Optina Diagnostics Closes CA$24.8M Series A Funding Round

Optina Diagnostics

Optina Diagnostics, a Montreal, Canada-based innovative diagnostics company leader in Retinal Imaging, Brain Health and Systemic Disease detection, closed a CA$24.8m Series-A funding round.

The round was led by DigitalDx Ventures with participation from Boehringer Ingelheim Venture Fund, Desjardins Capital, Hike Ventures, Advisors Fund, MEDTEQ+ and Biomed Propulsion (participative debt).

Led by David Lapointe, CEO, Optina Diagnostics has developed Retinal Deep PhenotypingTM┬áplatform, which obtained FDA Breakthrough Device Designation status in 2019 for its┬ánon-invasive and more accessible test to improve diagnosis accuracy and the management of patients undergoing evaluation for Alzheimer’s disease (AD).┬á

The Series A’s primary focus is to support the pivotal study for Optina’s awAIr┬áTM┬ácerebral amyloid status test when AD is suspected and will also support the platform development for early detection of systemic diseases. Funds will also be used to accelerate the deployment of additional clinical study sites with the installation of Optina’s Retinal Deep PhenotypingTM┬áplatform at leading institutions in┬áthe United States,┬áCanada, and┬áEurope.